Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Biogen Idec and Isis Pharmaceuticals are joining to develop an Isis antisense drug for the treatment of myotonic dystrophy type 1, the most common form of muscular dystrophy in adults. Isis’ goal is to correct the underlying defect in the dystrophia myotonica-protein kinase (DMPK) gene that causes the disease. Isis will receive $12 million and is eligible for $59 million in milestone payments. Biogen Idec has the option to license the drug from Isis at any time before the completion of Phase II clinical trials.
This article has been sent to the following recipient: